Maria N Gamaletsou1, Blandine Rammaert2, Marimelle A Bueno3, Brad Moriyama4, Nikolaos V Sipsas5, Dimitrios P Kontoyiannis6, Emmanuel Roilides7, Valerie Zeller8, Roberta Prinapori9, Saad J Taj-Aldeen10, Barry Brause11, Olivier Lortholary2, Thomas J Walsh12. 1. Weill Cornell Medical Center of Cornell University, New York, NY, USA; National and Kapodistrian University of Athens, Athens, Greece; Center for Osteoarticular Mycoses, Hospital for Special Surgery, New York, NY, USA; International Osteoarticular Mycoses Study Consortium, USA. 2. Center for Osteoarticular Mycoses, Hospital for Special Surgery, New York, NY, USA; International Osteoarticular Mycoses Study Consortium, USA; Université Paris-Descartes, Sorbonne Paris Cité, APHP, Service des Maladies Infectieuses et Tropicales, Hôpital Necker-Enfants Malades, Centre d'Infectiologie Necker-Pasteur, Institut Imagine, Paris, France; Unité de Mycologie Moléculaire, Institut Pasteur, Paris, France. 3. Weill Cornell Medical Center of Cornell University, New York, NY, USA. 4. Department of Pharmacy, NIH Clinical Center, Bethesda, MD, USA. 5. National and Kapodistrian University of Athens, Athens, Greece; Center for Osteoarticular Mycoses, Hospital for Special Surgery, New York, NY, USA; International Osteoarticular Mycoses Study Consortium, USA. 6. MD Anderson Cancer Center, Houston, TX, USA. 7. Center for Osteoarticular Mycoses, Hospital for Special Surgery, New York, NY, USA; International Osteoarticular Mycoses Study Consortium, USA; Infectious Diseases Unit, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, and Hippokration Hospital, Thessaloniki, Greece. 8. Osteoarticular Reference Center, Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, France. 9. Infectious Disease Department, San Martino di Genoa Hospital, University of Genoa, Genoa, Italy. 10. Mycology Unit, Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar. 11. Weill Cornell Medical Center of Cornell University, New York, NY, USA; Center for Osteoarticular Mycoses, Hospital for Special Surgery, New York, NY, USA; International Osteoarticular Mycoses Study Consortium, USA. 12. Weill Cornell Medical Center of Cornell University, New York, NY, USA; Center for Osteoarticular Mycoses, Hospital for Special Surgery, New York, NY, USA; International Osteoarticular Mycoses Study Consortium, USA. Electronic address: thw2003@med.cornell.edu.
Abstract
BACKGROUND: The epidemiology, pathogenesis, diagnosis, and management of Aspergillus osteomyelitis are not well understood. METHODS: Protocol-defined cases of Aspergillus osteomyelitis published in the English literature were reviewed for comorbidities, microbiology, mechanisms of infection, clinical manifestations, radiological findings, inflammatory biomarkers, antifungal therapy, and outcome. RESULTS: Among 180 evaluable patients, 127 (71%) were males. Possible predisposing medical conditions in 103 (57%) included pharmacological immunosuppression, primary immunodeficiency, and neutropenia. Seventy-three others (41%) had prior open fracture, trauma or surgery. Eighty (44%) followed a hematogenous mechanism, 58 (32%) contiguous infections, and 42 (23%) direct inoculation. Aspergillus osteomyelitis was the first manifestation of aspergillosis in 77%. Pain and tenderness were present in 80%. The most frequently infected sites were vertebrae (46%), cranium (23%), ribs (16%), and long bones (13%). Patients with vertebral Aspergillus osteomyelitis had more previous orthopedic surgery (19% vs 0%; P = 0.02), while those with cranial osteomyelitis had more diabetes mellitus (32% vs 8%; P = 0.002) and prior head/neck surgery (12% vs 0%; P = 0.02). Radiologic findings included osteolysis, soft-tissue extension, and uptake on T2-weighted images. Vertebral body Aspergillus osteomyelitis was complicated by spinal-cord compression in 47% and neurological deficits in 41%. Forty-four patients (24%) received only antifungal therapy, while 121 (67%) were managed with surgery and antifungal therapy. Overall mortality was 25%. Median duration of therapy was 90 days (range, 10-772 days). There were fewer relapses in patients managed with surgery plus antifungal therapy in comparison to those managed with antifungal therapy alone (8% vs 30%; P = 0.006). CONCLUSIONS: Aspergillus osteomyelitis is a debilitating infection affecting both immunocompromised and immunocompetent patients. The most common sites are vertebrae, ribs, and cranium. Based upon this comprehensive review, management of Aspergillus osteomyelitis optimally includes antifungal therapy and selective surgery to avoid relapse and to achieve a complete response.
BACKGROUND: The epidemiology, pathogenesis, diagnosis, and management of Aspergillus osteomyelitis are not well understood. METHODS: Protocol-defined cases of Aspergillus osteomyelitis published in the English literature were reviewed for comorbidities, microbiology, mechanisms of infection, clinical manifestations, radiological findings, inflammatory biomarkers, antifungal therapy, and outcome. RESULTS: Among 180 evaluable patients, 127 (71%) were males. Possible predisposing medical conditions in 103 (57%) included pharmacological immunosuppression, primary immunodeficiency, and neutropenia. Seventy-three others (41%) had prior open fracture, trauma or surgery. Eighty (44%) followed a hematogenous mechanism, 58 (32%) contiguous infections, and 42 (23%) direct inoculation. Aspergillus osteomyelitis was the first manifestation of aspergillosis in 77%. Pain and tenderness were present in 80%. The most frequently infected sites were vertebrae (46%), cranium (23%), ribs (16%), and long bones (13%). Patients with vertebral Aspergillus osteomyelitis had more previous orthopedic surgery (19% vs 0%; P = 0.02), while those with cranial osteomyelitis had more diabetes mellitus (32% vs 8%; P = 0.002) and prior head/neck surgery (12% vs 0%; P = 0.02). Radiologic findings included osteolysis, soft-tissue extension, and uptake on T2-weighted images. Vertebral body Aspergillus osteomyelitis was complicated by spinal-cord compression in 47% and neurological deficits in 41%. Forty-four patients (24%) received only antifungal therapy, while 121 (67%) were managed with surgery and antifungal therapy. Overall mortality was 25%. Median duration of therapy was 90 days (range, 10-772 days). There were fewer relapses in patients managed with surgery plus antifungal therapy in comparison to those managed with antifungal therapy alone (8% vs 30%; P = 0.006). CONCLUSIONS:Aspergillus osteomyelitis is a debilitating infection affecting both immunocompromised and immunocompetent patients. The most common sites are vertebrae, ribs, and cranium. Based upon this comprehensive review, management of Aspergillus osteomyelitis optimally includes antifungal therapy and selective surgery to avoid relapse and to achieve a complete response.
Authors: Caspar J Hodiamont; Koert M Dolman; Ineke J M Ten Berge; Willem J G Melchers; Paul E Verweij; Dasja Pajkrt Journal: Med Mycol Date: 2008-12-19 Impact factor: 4.076
Authors: Saad J Taj-Aldeen; Maria N Gamaletsou; Blandine Rammaert; Nikolaos V Sipsas; Valerie Zeller; Emmanuel Roilides; Dimitrios P Kontoyiannis; Michael Henry; Vidmantas Petraitis; Brad Moriyama; David W Denning; Olivier Lortholary; Thomas J Walsh Journal: Med Mycol Date: 2017-10-01 Impact factor: 4.076
Authors: Maria N Gamaletsou; Blandine Rammaert; Marimelle A Bueno; Nikolaos V Sipsas; Brad Moriyama; Dimitrios P Kontoyiannis; Emmanuel Roilides; Valerie Zeller; Saad J Taj-Aldeen; Michael Henry; Vidmantas Petraitis; David W Denning; Olivier Lortholary; Thomas J Walsh Journal: Med Mycol Date: 2017-04-01 Impact factor: 4.076
Authors: Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett Journal: Clin Infect Dis Date: 2016-06-29 Impact factor: 9.079
Authors: Pauline Comacle; Yohann Le Govic; Cyril Hoche-Delchet; Jeremy Sandrini; Claire Aguilar; Benjamin Bouyer; Sophie Blanchi; Pascale Penn Journal: Mycopathologia Date: 2016-04-02 Impact factor: 2.574
Authors: Sanjeet S Dadwal; Tobias M Hohl; Cynthia E Fisher; Michael Boeckh; Genofeva Papanicolaou; Paul A Carpenter; Brian T Fisher; Monica A Slavin; D P Kontoyiannis Journal: Transplant Cell Ther Date: 2021-03
Authors: Maria N Gamaletsou; Blandine Rammaert; Marimelle A Bueno; Nikolaos V Sipsas; Brad Moriyama; Dimitrios P Kontoyiannis; Emmanuel Roilides; Valerie Zeller; Saad J Taj-Aldeen; Andy O Miller; Ruta Petraitiene; Olivier Lortholary; Thomas J Walsh Journal: Open Forum Infect Dis Date: 2015-12-23 Impact factor: 3.835